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Abstract
Recent genetic studies and whole-genome sequencing projects have greatly improved
our understanding of human variation and clinically actionable genetic information.
Smaller ethnic populations, however, remain underrepresented in both individual and
large-scale sequencing efforts and hence present an opportunity to discover new vari-
ants of biomedical and demographic significance. This report describes the sequencing
and analysis of a genome obtained from an individual of Serbian origin, introducing
tens of thousands of previously unknown variants to the currently available pool. An-
cestry analysis places this individual in close proximity of the Central and Eastern
European populations; i.e., closest to Croatian, Bulgarian and Hungarian individuals
and, in terms of other Europeans, furthest from Ashkenazi Jewish, Spanish, Sicilian,
and Baltic individuals. Our analysis confirmed gene flow between Neanderthal and
ancestral pan-European populations, with similar contributions to the Serbian genome
as those observed in other European groups. Finally, to assess the burden of poten-
tially disease-causing/clinically relevant variation in the sequenced genome, we utilized
manually curated genotype-phenotype association databases and variant-effect predic-
tors. We identified several variants that have previously been associated with severe
early-onset disease that is not evident in the proband, as well as variants that could
yet prove to be clinically relevant to the proband over the next decades. The presence
of numerous private and low-frequency variants along with the observed and predicted
disease-causing mutations in this genome exemplify some of the global challenges of
genome interpretation, especially in the context of understudied ethnic groups.
1 Introduction
The genetic variation between individuals accounts for much of observed human diversity
and has the potential to provide information on phenotypic outcomes of clinical consequence.
∗Contributed equally to this work.
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Studies of genetic variation provided by individual genome sequences have revealed that this
variation differs both within and between populations, and also varies considerably depending
upon the population [8]. Moreover, characterization of genetic variation of individuals from
multiple populations has revealed a correlation between genetic and geographic distances,
and has become relevant for determining genetic ancestry and geographic origin [33, 23].
Therefore, the characterization of genetic variation has been of major interest for diverse
research fields, including medical, biological and anthropological sciences [5, 33, 14, 23, 22,
29].
Sequencing of the first human genomes revealed that most genetic variation is derived
from single nucleotide variants (SNVs), although insertions and deletions (indels) account for
the majority of the variant nucleotides [25]. The increased accessibility of DNA sequencing
has contributed to individual efforts from a range of distinct populations. To date, individual
genomes from American [25, 51], Han Chinese [48], Russian [6], African [39], Japanese [13],
German [43], Gujarati Indian [18], Estonian [27], Pakistani [2] and Mongolian [3] populations
have been sequenced and analyzed, among many others [8].
Larger-scale efforts to characterize human genetic variation have demonstrated that in-
dividuals from different populations carry particular combinations of rare and low frequency
variants. The 1000 Genomes Project Consortium has estimated that 86% of all variants are
confined to a single continental group and that about 10% of variants observed in a popula-
tion are private to that population [8]. Population-specific variants have the potential to be of
both functional and biomedical importance [5]. Furthermore, evidence of biologically mean-
ingful population-specific variation [16] emphasizes the need for ethnically relevant reference
genomes, as has been performed, for example, for the Korean population [7]. Although we
are not claiming to have introduced a new reference genome here, it is nevertheless important
to expand our sequencing efforts across diverse populations, particularly those that have not
been previously studied [36, 29].
In this paper, we describe the sequencing of the first genome of an individual of Serbian
origin, a member of a relatively small population in Central to Southeastern Europe. We
identify tens of thousands of novel genetic variants in this individual, more than a hundred of
which map to protein-coding regions and several hundred of which reside in close proximity
to gene coding regions. The extent of observed genetic variation allowed comparisons with
extant European populations and reaffirms support for the hypothesis of close correspon-
dence between genetic and geographic distances [33]. These results contribute to ongoing
efforts to understand human genetic variation and its geographic distribution, as well as
placing the Serbian genome within the context of the broader European population struc-
ture. Testing for Neanderthal introgression in the genome, we find evidence suggesting gene
flow from Neanderthal to an ancestral pan-European genome, with the Serbian genome be-
ing placed within range of other European populations. After variant annotation, we assess
the burden of potentially pathogenic variation present in this genome and identify variants
of putative clinical and pharmacogenetic relevance. Finally, we draw conclusions pertain-
ing to the phenotypic consequences and biomedical interpretation of individually sequenced
genomes.
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2 Materials and Methods
Donor information
The individual whose genome was sequenced and analyzed is of Serbian descent. The data,
both derived and raw, are publicly available through the Personal Genome Project website
[4], participant ID: hu3BDC4B.
Sample collection and DNA sequencing
Two milliliters of saliva were self-collected by the donor and stored using the DNA Genotek
Oragene DISCOVER (OGR-500) sample collection kit. Extraction of DNA from the sample
and subsequent sequencing were performed at the BGI (Shenzhen, China) on an Illumina
HiSeq 2000 sequencer, using standard protocols. To minimize the likelihood of systematic
bias in sampling, two libraries were prepared with an insert size of 500 bp each, with paired-
end reads of length 90 bp. Sequencing was then carried out in four lanes for each library to
ensure at least 30-fold coverage.
Read mapping and variant calling
The paired end reads were aligned to the GRCh37 human reference genome with the Burrows-
Wheeler Aligner (BWA-MEM) [26] and Bowtie2 [21]. Picard tools [1] were used for the
removal of duplicates followed by the use of two variant callers. GATK [30] was applied for
base quality score recalibration, indel realignment, genotyping and variant quality score re-
calibration according to GATK Best Practices recommendations [44, 11]. We also generated
results from Platypus [38] applied to the output from each aligner.
As described later in Results, variants identified through a combination of BWA and
GATK were used for all analyses. Variants in the intersection of all four pipelines were
considered to be confidently identified. All variant calls were subsequently annotated with
information from NCBI RefSeq using ANNOVAR [49].
Principal component analysis
Principal component analysis (PCA) was carried out using the smartpca program from
EIGENSOFT (v6.0.1; https://github.com/DReichLab/EIG), on the Serbian genome com-
bined with the SNV data (600,841 loci) from Lazaridis et al. [23]. Only the subset of
European individuals from their curated fully public dataset was used, reducing the original
set of 1,964 individuals to 260. A projection to the first two principal components was used
to establish the correspondence between genetic and geographic distance in our results.
Neanderthal introgression
To test for Neanderthal introgression in the Serbian genome, we computed D-statistics
[15, 41] using this genome and the dataset from Lazaridis et al. [22]. This dataset includes 294
ancient individuals (only one of which was used here) and a diverse set of 2,068 present-day
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humans, genotyped on the Affymetrix Human Origins array. Both the archaic and modern
genotype data were provided in the PACKEDANCESTRYMAP format, and were combined
using themergeit program from EIGENSOFT (v6.1.2; https://github.com/DReichLab/EIG).
The merged dataset, in total, contains 2,362 samples genotyped at 621,799 SNV loci. As
requested, we completed the consent form and obtained approval from David Reich’s labo-
ratory before using this dataset. We further note that some individuals from the study of
Lazaridis et al. [22] could not be included due to consent issues relating to data distribution.
We next genotyped the Serbian genome against these predefined SNVs using GATK
UnifiedGenotyper (v3.3-0-g37228af; [11]), following the same reference-bias free genotyping
protocol as used by the Simons Genome Diversity Project [28]. We converted the resulting
VCF files to the EIGENSTRAT format using VCFtools (v0.1.12a, [9]), and integrated the
Serbian genotype with the modern and ancient datasets. Finally, we ran qpDstat from
AdmixTools (default setting, v701) to calculate D-statistics and to test for Neanderthal gene
flow in the Serbian genome [41].
Burden of pathogenic variation
Variants of putative clinical significance were identified using genotype-phenotype databases
as well as computational variant-effect prediction. Manually curated genotype-phenotype
databases, such as the Human Gene Mutation Database (HGMD) [42] and PharmGKB [19],
annotate variants with a known relationship to phenotype [52, 42]. Clinical Annotations
from PharmGKB were compared against dbSNP v142 rsIDs [40] obtained using the an-
notate variation.pl script in ANNOVAR and avsnp142. Variants identified by GATK were
compared against HGMD to identify potentially disease-causing and disease-associated mu-
tations.
All variants in protein-coding regions were extracted and inputted to the MutPred suite
of tools [35, 34, 31]. The remaining variation observed in the proband was interrogated
using CADD [17]. For disease and gene ontology associations, the hypergeometric test in
WebGestalt was used with Benjamini-Hochberg correction for multiple hypothesis-testing
[47]. The background set that was used for these analyses included all protein-coding genes
from the human reference genome. For significance of an ontology term, it was also required
that at least five genes were associated with it.
3 Results
Effect of genotyping software
The selection of computational tools and their parameters in processing raw sequencing reads
can significantly impact the resulting genome and the entirety of subsequent analysis. To
understand the uncertainty of variant identification, we evaluated two different read mappers,
BWA [26] and Bowtie2 [21], and two different variant callers, GATK [30] and Platypus [38].
The results from four different platforms are contrasted in Figure 1. The SNV calling
shows good concordance between both read mappers and variant callers, with a large pro-
portion of variants identified by either platform being identified by all platforms. Using the
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Figure 1: Venn diagrams showing the total numbers of identified variants using two read
mappers (BWA [26], Bowtie2 [21]) and two variant callers (GATK [30], Platypus [38]).
BWA mapper, for example, 2,991,390/3,280,434 = 91.2% of SNVs identified by GATK were
also identified by Platypus and 89.1% of SNVs identified by Platypus were also identified by
GATK (Figure 1). Indel calling, on the other hand, is less reliable, with 401,082/627,519 =
63.9% variants identified by GATK also identified by Platypus and only 66.7% of variants
identified by Platypus being also identified by GATK. The influence of read mappers was
markedly lower; i.e., using the GATK mapper, we found that 95.1% of SNVs and 89.3% of
indels identified with BWA were also identified with Bowtie2, and that 98.3% SNVs and of
97.6% of indels identified with Bowtie2 were also identified with BWA. Smaller percentages
of overlap were observed for Platypus. Based on the results observed in this work and the
extent of usage of these tools in resequencing human genomes, we selected BWA+GATK as
our main platform.
Identification of genetic variants
The genome of a Serbian individual was sequenced according to the protocols described in
Materials and Methods, with all 22 autosomes having similar coverage (and the X and Y
chromosome having approximately half this coverage). The genome sequencing and map-
ping achieved an average read depth of 34.7, with 98.3% of GRCh37 reference bases having
coverage of 10-fold or more and 89.4% having coverage of 20-fold or more. When only the
non-zero positions were considered, the average read depth was 34.8, with 98.5% of GRCh37
reference bases having coverage of 10-fold or more and 89.7% having coverage of 20-fold or
more. The number of zero-depth positions were 7,649,443 (0.3%). The coverage distribution
is shown in Supplementary Figure 1.
Using the BWA+GATK pipeline, we identified a total of 3,908,814 variants in the Ser-
bian genome, of which 2,195,638 (56.2%) were heterozygous with one non-reference allele,
23,095 (0.6%) were heterozygous with two non-reference alleles, and 1,690,081 (43.2%) were
homozygous for a non-reference allele. The reported variants passed all quality filters of
GATK (marked as “PASS”) and were subsequently mapped to GRCh37 human reference
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Table 1: Summary of identified variants using BWA+GATK. Variants not present in gno-
mAD [24] are listed as novel and variants identified by all four genotyping platforms are
listed as confident.
Type of Variant Variant Novel Confident
variants
Confident
novel
upstream 23094 320 16211 90
upstream; downstream 881 8 624 4
UTR5 5205 54 4055 22
UTR5; UTR3 16 1 12 0
exonic 20706 145 17114 115
exonic; splicing 33 1 22 0
splicing 151 0 107 0
intronic 1410507 20531 1078226 4336
UTR3 31066 409 24095 101
downstream 26685 398 19351 61
ncRNA exonic 13064 129 9520 30
ncRNA exonic; splicing 3 0 2 0
ncRNA intronic 235936 3376 173168 832
ncRNA splicing 65 1 51 0
ncRNA UTR5 1 1 0 0
intergenic 2164496 34779 1597484 6848
genomic regions using ANNOVAR [49]. It is important to mention that ANNOVAR considers
all heterozygous positions with both alternative alleles as two different variants. Therefore,
the resulting genome contains 3,931,909 total variants, of which 2,940,042 (74.8%) were
identified by all four platforms and are considered to be confident identifications. Unsur-
prisingly, the majority of identified variants were found to reside in intergenic and intronic
regions (Table 1).
To identify novel variation, we searched the identified variants against the Genome Aggre-
gation Database (gnomAD) [24]. We found that 1.5% (60,153) all variants and 0.4% (12,439)
of confident variants were not present in gnomAD. We shall refer to these variants as “novel”
and “confident novel” variants, respectively. The breakdown of all variants and novel variants
with respect to genomic location is shown in Tables 1-2. The percentage of novel variants
varied across categories, comprising 0.9% (80) of nonsynonymous variants, 0.4% of synony-
mous variants, 0.7% (145) of exonic variants, 1.5% (20,531) of intronic variants, and 1.6%
(34,779) of intergenic variants. We found that 45.0% (9,328/20,739) of the exonic variants
were nonsynonymous, whereas 50.1% (10,381/20,739) were synonymous. Similar fractions
were observed for the confident variants (44.1% vs. 52.3%). Of the 3,871,756 GATK variants
which are also observed in the gnomAD database, 3,805,264 (95%) of these variants are
annotated to have allele frequency greater than 1% in gnomAD and 3,676,638 (95%) with
allele frequency greater than 5%.
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Table 2: Summary of identified exonic variants using BWA+GATK. Variants not present in
gnomAD [24] are listed as novel and variants identified by all four platforms are listed as
confident.
Type of Variant Variants Novel Confident
variants
Confident
novel
synonymous SNV 10381 42 8965 36
nonsynonymous SNV 9328 80 7559 69
nonframeshift deletion 137 2 62 0
nonframeshift insertion 117 3 58 0
frameshift deletion 103 6 45 4
frameshift insertion 74 3 37 1
stopgain 87 6 54 4
stoploss 11 0 9 0
unknown 501 4 347 1
Genetic variation and geographic distance
The projection of the Serbian individual to the first and second principal components against
European groups from [23] confirms that individuals from the same geographic region clus-
ter together (Figure 2). We clearly distinguish clusters of major populations composed of
individuals from the same region, approximately mirroring a map of Europe. The PCA plot
demonstrates that the genetic ancestry of the Serbian individual analyzed in the present
study corresponds to its geographic distance from other populations. It is positioned in close
proximity of the Croatian, Bulgarian, and Hungarian populations.
A somewhat surprising finding is the similarity of distances between the Serbian individ-
ual and other mostly Slavic populations (Russian, Belarus, Ukrainian) relative to distances
to various Central, Western, and Southern European groups (Czech, French, English, Alba-
nian, Greek). The average Euclidean distance and variance between the Serbian individual
and each of the available populations in the two-dimensional space of major PCA compo-
nents is as follows: Croatian (0.016826± 0.010526), Bulgarian (0.033603± 0.000225), Hun-
garian (0.037121± 0.000177), Czech (0.053687± 0.000033), Albanian (0.058875± 0.000117),
Ukrainian (0.064328±0.000062), Belarusian (0.069803±0.000043), Greek (0.071108±0.00062),
Tuscan (0.0736441±0.000028), French (0.083077±0.000159), English (0.084570±0.000142),
Norwegian (0.092721±0.00088), Russian (0.095968±0.000079), Estonian (0.098421±0.000046),
Finnish (0.108523±0.000154), Sicilian (0.120370±0.000481), Spanish (0.134602±0.000776),
Ashkenazi (0.156692± 0.000538). The three closest individuals to the Serbian genome were
of Croatian ancestry (0.0038, 0.0046, and 0.0108).
We note that combining the Serbian individual with the set of 260 European individuals
from Lazaridis et al. [23] caused 50 formerly biallelic sites to become triallelic (no monoallelic
sites became triallelic). The triallelic sites were removed from the analysis, leaving 600,791
sites in the analysis. The smartpca program was applied to the 261-by-600,791 genotype
matrix.
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Serbian individual
Figure 2: Principal component analysis (PCA) plot showing the proximity of the genome
sequenced in this study to other European genomes. As observed in previous studies [33, 23],
genomic distance correlates with geographic distance.
Gene flow with Neanderthals
Comparisons between Neanderthals and modern humans have previously revealed evidence
of gene flow from Neanderthals to Europeans [15, 41, 37, 12]. To test whether the Serbian
genome shares an excess of alleles with the Neanderthal genome, we integrated the Serbian
genotype with a published panel of ancient and modern humans (Materials and Methods).
We calculated D-statistics as a formal test for gene flow based on a four-taxon phylogeny,
D(P1, P2, P3, O), where Pi (i ∈ {1, 2, 3}) are populations and O is an outgroup. Given
a scenario where gene flow is absent, the derived alleles of P3 are expected, with equal
likelihood, to match those of P1 and P2; i.e., D = 0. Alternatively, either P1 or P2 could
share alleles with P3 more often than not, in which case D deviates from zero.
We computed D(Yoruba, Serbian,Altai,Chimpanzee) for testing for gene flow between
Neanderthals (“Altai”) and the given Serbian genome. We expected a positive D value,
given previous evidence that Neanderthals exchanged more alleles with Europeans than with
Africans. The test returned a D value of 0.0241±0.004476, which significantly deviated from
zero (Z-score = 5.39; Table 3), suggesting gene flow between Neanderthal and the lineage
leading to the Serbian genome. To validate this result, we also ran the test for other European
populations (Table 3). D-statistics calculated for French, Greek, and Russian genomes were
comparable to our result, all falling within the expected range of values reported in previous
studies [15, 37, 12].
We further attempted to ensure that the calculated D-statistics were unbiased. To do so,
we repeated the analysis by replacing Yoruba with Mbuti, as some of the Yoruba samples
could have had some recent European admixture. The calculation for D(Mbuti, Serbian,
Altai, Chimpanzee) yielded a D value of 0.0186 ± 0.004763 (Z-score = 3.99; Table 3), con-
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Table 3: Testing gene flow with Neanderthals. The results show the D-statistic (D), its
standard error (SE) and Z-score (Z) for the test using the set of populations P1, P2, and P3,
with Chimpanzee as an outgroup (O). The last two columns show ABBA vs. BABA counts
over the four genomes (P1, P2, P3, O).
P1 P2 P3 O D SE Z-score ABBA BABA
Yoruba Serbian Altai Chimpanzee 0.0241 0.004476 5.393 18158 17302
Yoruba French Altai Chimpanzee 0.0266 0.003012 8.821 18284 17338
Yoruba Greek Altai Chimpanzee 0.0270 0.003034 8.906 18266 17305
Yoruba Russian Altai Chimpanzee 0.0288 0.003096 9.306 18328 17302
Mbuti Serbian Altai Chimpanzee 0.0186 0.004763 3.909 18817 18129
Mbuti French Altai Chimpanzee 0.0210 0.003532 5.941 18902 18125
Mbuti Greek Altai Chimpanzee 0.0214 0.003578 5.978 18897 18106
Mbuti Russian Altai Chimpanzee 0.0232 0.003600 6.434 18932 18074
sistent with our results using the Yoruba samples. We next checked whether the Serbian
individual has reference biases in genotyping that could have inflated the D value. We
performed D-statistics tests in the form of D(other European population, Serbian, Mbuti,
hg19ref) and chose French, Greek and Russian as the “other European population”. We ob-
tained no test results indicating the bias of Serbian genotypes toward the reference (French:
0.0038± 0.004078; Greek: 0.0090± 0.004182; Russian: 0.0074± 0.004192).
Analysis of medically relevant variants
The sequenced genome contains 2,344 genetic variants that are present in HGMD by virtue
of their having been previously associated with a risk of disease; the proportions of variants
within each effect category are shown in Table 4. Several homozygous variants, manu-
ally annotated as disease-causing (DM) are observed in the genome, shown in Table 5. Of
these, two are youth-onset phenotypes that are homozygous for the disease-causing allele
in the proband genome: nephropathic cystinosis (NP 004928.2:p.T260I) and Factor XIII
deficiency (NM 000129.3:c.-19+12C>A). The disease phenotypes associated with these ho-
mozygous mutations typically become apparent in childhood, and therefore their occurrence
in a healthy adult is indicative of variable penetrance. The other homozygous disease-causing
variants result in phenotypes that have not yet been observed in either the individual or in
that individual’s family history, perhaps reflecting either low expressivity or late-onset. Ob-
served heterozygous disease-causing mutations are primarily childhood-onset without pre-
sentation in the individual, although they may represent recessive conditions; thus, their
failure to manifest may not necessarily be indicative of poor reporting or curation quality.
We also identified several variants of potential pharmacogenetic relevance using Phar-
mGKB. Variants in PharmGKB are assigned Clinical Annotation Levels of Evidence from
variants with preliminary evidence (Level 4) to high confidence variant-drug combinations
with medically endorsed integration into health systems (Level A1). The genome contains a
single variant with a high confidence annotation (Level 1B): rs2228001, associated with toxi-
city and adverse drug reaction to cisplatin, a chemotherapeutic agent. A further 17 variants
were annotated with moderate evidence to impact the dosage, efficacy, metabolism and/or
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Table 4: Amount of disease-causing and potentially disease-relevant variation in the Serbian
genome. Identified variants were searched against HGMD and broken down into the pheno-
typic categories of HGMD. Variants were broken down into exonic and noncoding as well as
homozygous and heterozygous.
Exome Noncoding
Hom Het Hom Het
Disease-causing mutations (DM) 2 9 4 6
Likely disease-causing mutations (DM?) 29 51 8 31
Disease-associated polymorphisms with additional
supporting functional evidence (DFP)
78 139 203 301
Disease-associated polymorphisms (DP) 233 356 189 322
Polymorphisms that affect gene/protein structure,
function or expression but with no reported disease
association (FP)
63 95 95 130
The number of homozygous and heterozygous variants that are associated with variants reported in
HGMD. HGMD labels correspond to the strength and/or evidence for the relationship between variant and
disease.
Table 5: Disease-causing variants observed in the proband. The table contains analysis of six
homozygous variants form the sequenced genome that are listed in HGMD as disease-causing.
Gene Variant rsID Phenotype
MIR137HG NC 000001.10:g.98502934G>T rs1625579 Schizophrenia increased risk
SLC12A3 NM 000339.2:c.1670-8C>T NA Gitelman syndrome without
hypomagnesaemia
DUOXA2 NM 207581.3:c.554+6C>T NA Hypothyroidism
F13A1 NM 000129.3:c.-19+12C>A rs2815822 Factor XIII deficiency
CTNS NP 004928.2:p.T260I NA Cystinosis nephropathic
PNPLA2 NP 065109.1:p.P481L rs1138693 Myopathy late-onset
toxicity of drugs for diverse phenotypes including chronic hepatitis C, organ transplantation
rejection, glaucoma, depression, schizophrenia, asthma, epilepsy and HIV infections, as well
as several chemotherapy drugs.
Pathogenicity prediction
In addition to known disease-associated variants, we identified missense variants predicted
to be pathogenic by MutPred2 [35]. Of the 11,206 missense variants called by GATK, 9,329
passed all quality filters (annotated as ‘PASS’). Of these, 9,305 variants were unambiguously
mapped to the correct protein isoforms and hence were amenable for prediction by MutPred2.
Based on a score threshold of 0.8 (estimated 5% false positive rate), 95 missense variants
were predicted to be ‘pathogenic.’ Of these, 14 variants were found in the homozygous state
and 81 were found in the heterozygous state. Genes for these variants were enriched in
GO terms related to peptidase activity (Supplementary Figure 2). A similar analysis for
disease associations revealed that the subject may be at risk for cardiovascular disorders
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(Supplementary Table 1).
We assessed the pathogenicity of 180 nonsense and frameshifting insertion and deletion
variants with MutPred-LOF [34]. From this set, we identified a total of 7 variants with scores
above the 0.5 score threshold (corresponding to a 5% false positive rate) (Supplementary
Table 2). We also assessed the pathogenicity of the 90 SNV splicing variants with MutPred
Splice [31]. Of these, 28 of the variants are scored at least 0.6 and were therefore classified
as a “Splice Affecting Variant” by MutPred Splice. Of these, one variant is predicted to
cause loss of natural 3’ splice sites, two variants are predicted to interrupt cryptic 3’ splice
sites, and three variants are predicted to disrupt cryptic 5’ splice sites. These 28 variants
are described in Supplementary Table 3.
To ensure assessment of the complete variome of the proband, we utilized CADD v1.3
[17] to evaluate all noncoding variants. To do so, we utilized a scaled C-score cutoff of 20 to
identify the 1% most damaging variants. In total, we found 16 UTR variants, 1,630 intronic
variants, 3,911 intergenic variants, 80 regulatory variants, 839/533 upstream/downstream
variants, and 9 variants annotated as “noncoding change.” All of these were predicted to be
deleterious. The noncoding variants with the highest C-scores are described in Supplemen-
tary Table 4.
4 Discussion
This work describes the first whole-genome sequencing of a Serbian individual. Ancestry
analysis positioned the Serbian individual in closest proximity to the Croatian population,
consistent with its South Slavic ancestry [20]. Our analyses further support the hypothesis
of gene flow between Neanderthal and pan-European ancestral populations, with the level
of introgression into the Serbian genome being within the range observed in other European
populations. Previous genetic studies involving Slavic populations employed mitochondrial,
Y-chromosome and SNV-panel data to investigate the relationship between geographic, ge-
netic and linguistic distances [20, 10]. Consistent with this work, our analyses expand the
scope beyond Slavic populations and further contribute to the understanding of human ge-
netic variation and its geographic distribution.
In contrast to studies using genotyping arrays [33, 23, 20, 10], the availability of whole-
genome sequences presents the opportunity for a high-resolution individualized analysis. To
this end, we found that the sequenced genome contains a significant number of previously
unobserved variants, which emphasizes the importance of continued sequencing of a large
number of individuals, especially from smaller ethnic groups. Subsequent sequencing of other
Serbian individuals could provide further insight into these novel variants; e.g., whether they
are private to the population or to the individual. Such results would in turn contribute
important information regarding variants that are currently considered to be rare, with im-
plications for improved variant interpretation. Furthermore, new algorithms and reduced
sequencing costs will have the potential to provide higher-quality analysis of structural vari-
ants that has not been possible in this work. Our analysis also found a number of variants of
clinical and pharmacogenomic significance that might extend beyond an individual’s disease
risks to facilitate possible future medical interventions. Such variants might contribute to
better outcomes in studies of disease penetrance, mechanistic understanding of population
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risks, and database curation.
Recent advances in high-throughput sequencing and reduced costs of genotyping have
greatly facilitated whole-genome data generation, and have become key to understanding
both human phenotypes and early human history [33, 23]. However, modern technology and
cost structure continue to pose challenges in determining and interpreting one’s genome [45].
Variation in read mapping and variant calling contribute to the uncertainty of interpreta-
tion with different software packages, identifying different sets of variants. We found that
inter-software discrepancies ranged from relatively small for SNVs to considerable for inser-
tions and deletions. Therefore, variant and genome interpretation demand caution, since
thousands of SNVs and tens of thousands of indels may simply constitute genotyping errors
[32, 46].
It is worth mentioning that in addition to the technical aspects of genome sequencing, an
important aspect of genome interpretation concerns psychosocial uncertainty due to pheno-
typic and privacy-associated risks [50]. This study has provided demographic analysis that
supports the individual’s own sense of Serbian ancestry; however, the finding of multiple pre-
dicted youth-onset pathogenic mutations in a healthy individual provides cautionary lessons
for predictive medicine.
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